Credit Suisse Group Initiates Coverage on Johnson & Johnson (NYSE:JNJ)

Equities research analysts at Credit Suisse Group began coverage on shares of Johnson & Johnson (NYSE:JNJ) in a research note issued on Friday, BenzingaRatingsTable reports. The firm set an “outperform” rating and a $156.00 price target on the stock. Credit Suisse Group’s target price would suggest a potential upside of 11.34% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. Wells Fargo & Co increased their price target on shares of Wingstop from $76.00 to $84.00 and gave the company an “outperform” rating in a research note on Monday, May 6th. Zacks Investment Research raised shares of Jack Henry & Associates from a “sell” rating to a “hold” rating in a research note on Wednesday, March 27th. Raymond James set a $8.00 price target on shares of Superior Energy Services and gave the company a “buy” rating in a research note on Wednesday, April 17th. Barclays increased their price target on shares of from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the company an “equal weight” rating in a research note on Friday, June 21st. Finally, BMO Capital Markets initiated coverage on shares of Yelp in a report on Wednesday, April 17th. They issued an “outperform” rating on the stock. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $149.89.

Shares of NYSE JNJ opened at $140.11 on Friday. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.99. The stock has a market cap of $374.92 billion, a PE ratio of 17.13, a PEG ratio of 2.44 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.13 and a current ratio of 1.44. The company’s 50-day simple moving average is $138.94.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.07. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The business had revenue of $20.02 billion during the quarter, compared to analysts’ expectations of $19.55 billion. During the same quarter in the prior year, the company posted $2.06 EPS. The business’s revenue for the quarter was up .1% on a year-over-year basis. On average, research analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

In related news, Director Marillyn A. Hewson acquired 3,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The shares were purchased at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the acquisition, the director now owns 3,000 shares in the company, valued at approximately $419,040. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.23% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Evolution Wealth Advisors LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $40,000. Horan Securities Inc. lifted its holdings in Johnson & Johnson by 122.3% during the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after buying an additional 241 shares in the last quarter. Stuart Chaussee & Associates Inc. lifted its holdings in Johnson & Johnson by 20.7% during the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after buying an additional 80 shares in the last quarter. Thor Advisors LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $69,000. Finally, FNY Investment Advisers LLC lifted its holdings in Johnson & Johnson by 594.4% during the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock worth $64,000 after buying an additional 428 shares in the last quarter. Institutional investors own 66.85% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Google Finance Portfolio Tips and Tricks

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply